Expert Perspectives on Improving Treatment of Patients with B-Cell Non-Hodgkin Lymphomas
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. This heterogenous group of lymphoproliferative disorders remains a challenge to treat due to differing patterns of behavior and responses to treatment. Indolent lymphomas have a good prognosis if caught early, but many patients are not diagnosed until they have a more advanced stage of disease. While approximately 50% of patients with aggressive NHL can be cured, many patients relapse within the first 2 years of treatment. The ever-evolving treatment landscape of NHL provides clinicians new and potentially efficacious approaches with which to treat these challenging cases, but selecting a treatment that meets both the clinician’s and the patient’s goals remains challenging.
This CME/CE accredited activity provides healthcare providers with much needed professional education on treatment algorithms; recent clinical advances, emerging treatments, and clinical trials; as well as considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs.
After completing this program, participants should be able to:
1. Summarize current best-practice approaches for treatment of patients with different subtypes of indolent and aggressive B-cell non-Hodgkin lymphomas (NHLs)
2. Asses recent clinical advances and emerging treatment options for the management of B-cell NHLs, including next generation mAbs, BTK inhibitors, PI3K inhibitors, IMiDs, Bcl-2 inhibitors, and ongoing clinical trials
3. Evaluate patient, disease, and treatment-related considerations to optimize patient outcomes while providing the best standard of care for patients with B-cell NHLs
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this live activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this live activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Anas Younes, MD
Chief, Lymphoma Services
Memorial Sloan Kettering Cancer Center
Paul Hamlin, MD
Chief, Medical Oncology Service
Memorial Sloan Kettering Basking Ridge
Member, MSK Lymphoma Service
Eduardo Martin Sotomayor, MD
Director, George Washington Cancer Center
Parameswaran Venugopal, MD
Professor of Medicine
The Elodia Kehm Chair of Hematology
Director, Section of Hematology
Rush University Medical Center, Chicago, IL
Thomas E. Witzig, MD
Professor of Medicine Mayo Clinic College of Medicine
Co-PI, University of Iowa/Mayo Clinic Lymphoma SPORE
Deputy Director of Clinical Research, Mayo Clinic Cancer Center
Mitchell R. Smith, M.D., Ph.D.
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
George Washington University Cancer Center
Sarah Rutherford, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Inc., Celgene Corp., Novartis, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., AbbVie, Inc